770 related articles for article (PubMed ID: 17045355)
21. Particle size-dependent triggering of accelerated blood clearance phenomenon.
Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
[TBL] [Abstract][Full Text] [Related]
22. Accelerated clearance of a second injection of PEGylated liposomes in mice.
Ishida T; Masuda K; Ichikawa T; Ichihara M; Irimura K; Kiwada H
Int J Pharm; 2003 Apr; 255(1-2):167-74. PubMed ID: 12672612
[TBL] [Abstract][Full Text] [Related]
23. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
24. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
25. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
Shimizu T; Ishida T; Kiwada H
Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
[TBL] [Abstract][Full Text] [Related]
27. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL
Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968
[TBL] [Abstract][Full Text] [Related]
28. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.
Dams ET; Laverman P; Oyen WJ; Storm G; Scherphof GL; van Der Meer JW; Corstens FH; Boerman OC
J Pharmacol Exp Ther; 2000 Mar; 292(3):1071-9. PubMed ID: 10688625
[TBL] [Abstract][Full Text] [Related]
29. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
30. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
Ishida T; Harada M; Wang XY; Ichihara M; Irimura K; Kiwada H
J Control Release; 2005 Jul; 105(3):305-17. PubMed ID: 15908032
[TBL] [Abstract][Full Text] [Related]
31. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
32. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
[TBL] [Abstract][Full Text] [Related]
33. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
Charrois GJ; Allen TM
J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
[TBL] [Abstract][Full Text] [Related]
34. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
[TBL] [Abstract][Full Text] [Related]
35. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
[TBL] [Abstract][Full Text] [Related]
37. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
39. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
40. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies.
Bao A; Goins B; Klipper R; Negrete G; Phillips WT
J Pharmacol Exp Ther; 2004 Feb; 308(2):419-25. PubMed ID: 14610219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
